🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for HER2 Low Breast Carcinoma

Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients NCT06722599n/a1 site📍 Beijing Shu Wang Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast Cancer NCT07817082Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: SHR- A1811 Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer NCT07630402NA1 site📍 Rochester University of Rochester · Tests: Echocardiogram A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) NCT06330064Phase 1, Phase 2120 sites📍 Los Angeles📍 Los Angeles📍 Whittier Daiichi Sankyo · Tests: Ifinatamab deruxtecan Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer NCT06837792Phase 21 site📍 Seoul Yonsei University · Tests: Experimental treatment arm, Control treatment arm Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer NCT07276880Phase 21 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: Neoadjuvant Pembrolizumab, low dose neoadjuvant boost, High dose neoadjuvant boost PRE-ISPY Phase I/II Oncology Platform Program NCT05868226Phase 1, Phase 210 sites📍 Birmingham📍 Phoenix📍 Aurora QuantumLeap Healthcare Collaborative · Tests: ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138 A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer NCT07701941Phase 1, Phase 272 sites📍 Los Angeles📍 Stanford📍 Aurora Daiichi Sankyo · Tests: Patritumab deruxtecan, Trastuzumab deruxtecan Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer NCT06207734Phase 213 sites📍 Berlin📍 Bremen📍 Dortmund Institut für Klinische Krebsforschung IKF GmbH at Krankenha… · Tests: Continuation of CDK4/6 inhibitor Palbociclib, Discontinuation of CDK4/6 inhibitor Palbociclib, Continuation of CDK4/6 i… Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer NCT06665178Phase 21 site📍 Vancouver British Columbia Cancer Agency · Tests: Sacituzumab Govitecan ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer NCT06224673Phase 21 site📍 San Francisco Laura Huppert, MD, BA · Tests: ARX788, Computed Tomography (CT), Biospecimen Collection, Amiloride Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer NCT06642545Phase 21 site📍 Beijing RemeGen Co., Ltd. · Tests: Disitamab Vedotin, RC148, Albumin-bound Paclitaxone, Toripalimab A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer NCT06957886Phase 32 sites📍 Guangzhou📍 Changsha Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M07D1, Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel Implementation of Solid Digital PCR to Support Gold-standard Methods for Evaluation of HER2 Amplification Status: Focus on HER2-low Subtype NCT06813456n/a1 site📍 Bologna IRCCS Azienda Ospedaliero-Universitaria di Bologna TRUDI: TDXD+Durva in HER2+/Low IBC NCT05795101Phase 23 sites📍 Boston📍 Boston📍 Houston Filipa Lynce, MD · Tests: Trastuzumab deruxtecan, Durvalumab The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study NCT06254690Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Pyrotinib dose escalation, Pyrotinib dose normal Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer NCT06331169Phase 11 site📍 Shanghai Fudan University · Tests: Anlotinib, Trastuzumab deruxtecan ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer NCT07198724Phase 1, Phase 21 site📍 Boston Kristina A. Fanucci · Tests: Elacestrant, Trastuzumab Deruxtecan Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers NCT05846789Phase 27 sites📍 Atlanta📍 Carmel📍 Indianapolis Kathy Miller · Tests: SOC Chemotherapy, Tocilizumab/Tocilizumab Biosimilar Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer NCT07137416Phase 12 sites📍 Boston📍 St Louis National Cancer Institute (NCI) · Tests: Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan, Pidnarulex Analysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced/Metastatic Breast Cancer NCT06706557n/a1 site📍 Milan European Institute of Oncology A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer NCT05911958Phase 21 site📍 Zhengzhou Henan Cancer Hospital · Tests: SHR-A1811 for injection Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving Surgery NCT07762885Phase 31 site📍 Shanghai Fudan University · Tests: Adjuvant Radiotherapy, tamoxifen To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer NCT06389006Phase 21 site📍 Shanghai RemeGen Co., Ltd. · Tests: Disitamab Vedotin for Injection, Toripalimab, Epirubicin, Cyclophosphamide Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype NCT06486883Phase 279 sites📍 Graz📍 Linz📍 Vienna MedSIR · Tests: Trastuzumab deruxtecan (T-DXd, DS-8201a), CDK4/6i plus ET TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd NCT06533826Phase 211 sites📍 Birmingham📍 San Francisco📍 New Haven Ana C Garrido-Castro, MD · Tests: Trastuzumab Deruxtecan, Datopotamab Deruxtecan Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study NCT07446452Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Disitamab Vedotin (RC48), Bevacizumab Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI. NCT07195344Phase 410 sites📍 Angers📍 Dijon📍 Lille Institut Claudius Regaud · Tests: Pharmacokinetics blood samples A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence NCT06492616Phase 3567 sites📍 Daphne📍 Chandler📍 Gilbert Stemline Therapeutics, Inc. · Tests: Elacestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd NCT06298084Phase 1, Phase 21 site📍 Villejuif Gustave Roussy, Cancer Campus, Grand Paris · Tests: Patritumab deruxtecan, Olaparib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy